标题：Glycoengineering of Natural Killer Cells with CD22 Ligands for Enhanced Anticancer Immunotherapy
作者：Wang X.; Lang S.; Tian Y.; Zhang J.; Yan X.; Fang Z.; Weng J.; Lu N.;等 更多Wang X.; Lang S.; Tian Y.; Zhang J.; Yan X.; Fang Z.; Weng J.; Lu N.; Wu X.; Li T.; Cao H.; Li Z.; Huang X. 收起 作者机构：[Wang, X] Department of Biomaterials, College of Materials, Xiamen University, Xiamen, 361005, China;[ Lang, S] Depts. of Chem. and Biomed. Engineerin 更多[Wang, X] Department of Biomaterials, College of Materials, Xiamen University, Xiamen, 361005, China;[ Lang, S] Depts. of Chem. and Biomed. Engineering, Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, MI 48824, United States;[ Tian, Y] Xiamen Nuokangde Biological Technology Co., Ltd., Xiamen, 361006, China;[ Zhang, J] Xiamen Nuokangde Biological Technology Co., Ltd., Xiamen, 361006, China;[ Yan, X] School of Chemistry, Sun Yat-Sen University, Guangzhou, 510275, China;[ Fang, Z] Department of Hematology, First Affiliated Hospital of Xiamen University, Xiamen, 361003, China;[ Weng, J] Department of Biomaterials, College of Materials, Xiamen University, Xiamen, 361005, China;[ Lu, N] National Glycoengineering Research Center, Shandong University, Qingdao,Shandong, 266237, China;[ Wu, X] Depts. of Chem. and Biomed. Engineering, Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, MI 48824, United States, National Glycoengineering Research Center, Shandong University, Qingdao,Shandong, 266237, China;[ Li, T] Depts. of Chem. and Biomed. Engineering, Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, MI 48824, United States, National Glycoengineering Research Center, Shandong University, Qingdao,Shandong, 266237, China;[ Cao, H] National Glycoengineering Research Center, Shandong University, Qingdao,Shandong, 266237, China;[ Li, Z] Xiamen Nuokangde Biological Technology Co., Ltd., Xiamen, 361006, China;[ Huang, X] Depts. of Chem. and Biomed. Engineering, Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, MI 48824, United States 收起 通讯作者：Li, Z(lizhu@nkdbio.com)
通讯作者地址：[Li, Z] Xiamen Nuokangde Biological Technology Co., Ltd.China;
来源：ACS Applied Materials and Interfaces
出版年：2020
DOI：10.1021/acscentsci.9b00956
摘要：Adoptive transfer of immune cells is being actively pursued for cancer treatment. Natural killer (NK) cells, a class of cytotoxic immune cells, generally lack inherent selectivities toward cancer. To bestow tumor-targeting abilities and enhance anticancer efficacy, a new strategy is established to glycoengineer NK cells. Carbohydrate-based ligands for CD22, a marker for B cell lymphoma, are introduced onto NK cells through either metabolic engineering or glyco-polymer insertion. Such NK cells exhibited greatly enhanced cytotoxicities toward CD22+ lymphoma cells in a CD22-dependent manner. Importantly, both CD22+ lymphoma cell lines and primary lymphoma cells from human cancer patients can be effectively killed by the engineered NK cells. Furthermore, glycoengineered NK cells provided significant protection to tumor-bearing mice. Thus, NK cell glycoengineering is an exciting new approach for cancer treatment complementing the current immune cell genetic engineering strategy. Copyright © 2020 American Chemical Society.
收录类别：SCOPUS
Scopus被引频次：3
资源类型：期刊论文
原文链接：https://www.scopus.com/inward/record.uri?eid=2-s2.0-85081643804&doi=10.1021%2facscentsci.9b00956&partnerID=40&md5=a7486675ce384122fae5a4a222ed6288
